News and Announcements
Proteomics International Laboratories Clinical Validation Study Confirms PromarkerD Performance
- Published June 13, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Proteomics International Laboratories Ltd (ASX: PIQ) (PILL) announced results from its validation clinical study showing that the PromarkerD blood test can predict the onset of diabetic kidney disease better than any current measure.
KEY TAKEAWAYS:
- PromarkerD test predicted 86% of previously disease-free patients who went on to develop chronic kidney disease within four years.
- Study is the largest prospective clinical study on diabetic kidney disease in the community and evaluated 792 patients over a four year period.
- Results presented at the American Diabetes Association’s 77th Annual Scientific Sessions in the Late-breaking Abstracts section of the conference, 9-13th June 2017, San Diego.
- If unchecked, the International Diabetes Federation predicts the ‘at risk’ population will be 642 million by 2040, and the number of diabetics with chronic kidney disease will rise by 76 million to 214 million.
- In March 2017, Frost & Sullivan identified PromarkerD as the world’s leading test for diabetic kidney disease.
- PromarkerD has the potential to save health systems around the world billions of dollars in costs associated with treating diabetic kidney disease.
- Commercialisation of the test proceeding which has the potential to deliver substantial revenues to PIQ in the form of licensing fees and royalties.
PromarkerD is a breakthrough blood test that uses a protein ‘fingerprint’ to measure kidney disease in patients with diabetes. This ground-breaking test can both diagnose and predict disease.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
